CUSIP 88032L605COM NEWTENXQ4 2025
43 filings · latest Mar 10, 2026
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Ikarian Capital, LLC | 967.6K | $11.80M |
| 2 | Morgan Stanley | 596.4K | $7.27M |
| 3 | Perceptive Advisors LLC | 439.1K | $5.35M |
| 4 | Siren, L.L.C. | 427.1K | $5.21M |
| 5 | Point72 Asset Management, L.P. | 423.4K | $5.16M |
| 6 | Rtw Investments, LP | 378.3K | $4.61M |
| 7 | Boothbay Fund Management, LLC | 352.2K | $4.29M |
| 8 | Bvf Inc/Il | 339.5K | $4.14M |
| 9 |
| 4 | Feb 17, 2026 | Venrock Healthcare Capital Partners III, L.P. | 13G/A | 9.9% | 693.0K | SEC |
| 5 | Feb 17, 2026 | Rtw Investments, LP | 13G/A | 9.9% | 651.0K | SEC |
| 6 | Feb 17, 2026 | Perceptive Advisors LLC | 13G/A | 9.1% | 569.3K | SEC |
| 7 | Feb 17, 2026 | Lind Global Fund II LP | 13G/A | 11.0% | 442.5K | SEC |
| 8 | Feb 17, 2026 | Biotechnology Value Fund L P | 13G/A | 10.0% | 768.2K | SEC |
| 9 | Feb 17, 2026 | Point72 Asset Management, L.P. | 13G/A | 6.8% | 423.4K | SEC |
| 10 | Feb 12, 2026 | Morgan Stanley | 13G | 9.6% | 596.4K | SEC |
See the full Schedule 13D/13G history for Tenax Therapeutics Inc.
Unlock full history| 302.5K |
| $3.69M |
| 10 | Marshall Wace, LLP | 298.2K | $3.63M |